Table 3.
Studies | Histological Diagnosis | Immuno-Histochemical Markers Used | Confirmed Primaries at Follow-Up |
---|---|---|---|
Matsunaga et al., 2019 [27] | 42 Adeno-K, 4 squamous-cells, 2 neuroendocrine | NS | NS |
Mavrakis et al., 2005 [6] | 7 Adeno-K, 2 poorly differentiated malignant epithelial tumours | NS | 2/9 (22%) |
Drlicek et al., 2004 [39] | Lung 5, colorectum 1, breast 1, kidney 1 | CK (AE1/AE3, 7, 10/13, 18, 20), vimentin, protein S100, TTF-1, and CA 15-3, 19.9, 125, PSA | 0 |
Bartelt and Lutterbach, 2003 [14] | 15 Lung Adeno-K,4 Squamous-cells, 4 Large-cells, 4 Small-cells, 20 Other | NS | NS |
Klee et al., 2002 [60] | 14 Adeno-K (12 CK 7 +, none CK 20), 1 carcinoma (no CK 7, CK 20 and CK), 1 melanoma | CK7, CK20, PSA, HCG, CA125 and “antibodies indicating breast or pulmonary primary” | 7/14 (50%) |
Rudà et al., 2001 [61] | 4 Lung Adeno-K, 1 Squamous-cells, 3 Colon Adeno-K, 1 Pancreatic Adeno-K, 18 no diagnosis | NS | 27/33 (81%) |
Maesawa et al., 2000 [17] | 10 Adeno-K, 2 Squamous-cells, 1 Clear-cells, 2 Undifferentiated | NS | 4/15 (26.7%) |
Nguyen et al., 1998 [18] | 31 Adeno-K, 2 small-cells,1 squamous-cells, 4 other, 1 missing | NS | 12/39 (31%) |
Salvati et al., 1995 [10] | 65 Adeno-K, 10 Squamous-cells, 10 Melanoma, 7 Undifferentiated, 7 other small-cells | NS | 64/100 (64%) |
Debevec, 1990 [44] | Anaplastic K and adeno-K were most frequent | NS | 47/75 (63%) |
Merchut, 1989 [7] | 8 Adeno-K + 1 squamous-cells | NS | 47/56 (84%) |
Chee and Byrnes, 1988 [4] | 5 Adeno-K, 3 anaplastic, 4 squamous-cells, 1 sarcoma, 1 transitional-cells | NS | 35/51 (68%) |
Eapen et al., 1988 [23] | 9 No diagnosis, 19 Adeno-K, 7 Squamous K, 5 Anaplastic K, 1 large-cells, 1 small-cells, 1 transitional-cells | NS | 11/43 (25%) |
Zimm et al., 1981 [28] | 14 Adeno-K, 2 squamous | NS | 10/16 (37%) |
NS = not specified, IHC = immunohistochemistry, K = carcinoma, Adeno-K = adenocarcinoma.